Design, Synthesis, and Evaluation of GLUT Inhibitors

  • Carlotta Granchi
  • Tiziano Tuccinardi
  • Filippo MinutoloEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1713)


The Warburg effect describes how most cancer cells exhibit higher-than-normal glucose consumption, not only under hypoxic conditions, but also when normal oxygen levels are present. Although glucose transporter 1 (GLUT1) has been found to play a key role in the cellular uptake of glucose, especially in cancer cells, where it is generally overexpressed, it has not been given consideration as a suitable target for the development of anticancer drugs. In this chapter, an example of molecular design and realization of novel GLUT1 inhibitors, including in silico modeling, chemical synthesis, and biological characterization, is provided. This process started with the identification of a focused series of oxime derivatives, originally designed as estrogen receptor (ER) ligands, which were structurally optimized in order to direct their activity towards GLUT1 and to minimize their binding to the ERs, leading to the production of efficient and selective inhibitors of glucose uptake in cancer cells.


Glucose transporters Warburg effect Inhibitors Cancer Molecular design Oximes 2-NBDG 


  1. 1.
    Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202(3):654–662. CrossRefPubMedGoogle Scholar
  2. 2.
    Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314CrossRefPubMedGoogle Scholar
  3. 3.
    Smith TA (2001) The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol 28(1):1–4CrossRefPubMedGoogle Scholar
  4. 4.
    Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8(9):705–713. CrossRefPubMedGoogle Scholar
  5. 5.
    Granchi C, Fortunato S, Minutolo F (2016) Anticancer agents interacting with membrane glucose transporters. Medchemcomm 7(9):1716–1729. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Granchi C, Qian Y, Lee HY, Paterni I, Pasero C, Iegre J, Carlson KE, Tuccinardi T, Chen X, Katzenellenbogen JA, Hergenrother PJ, Minutolo F (2015) Salicylketoximes that target glucose transporter 1 restrict energy supply to lung cancer cells. ChemMedChem 10(11):1892–1900. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Tuccinardi T, Granchi C, Iegre J, Paterni I, Bertini S, Macchia M, Martinelli A, Qian Y, Chen X, Minutolo F (2013) Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells. Bioorg Med Chem Lett 23(24):6923–6927. CrossRefPubMedGoogle Scholar
  8. 8.
    Bertini S, De Cupertinis A, Granchi C, Bargagli B, Tuccinardi T, Martinelli A, Macchia M, Gunther JR, Carlson KE, Katzenellenbogen JA, Minutolo F (2011) Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes. Eur J Med Chem 46(6):2453–2462. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Minutolo F, Bellini R, Bertini S, Carboni I, Lapucci A, Pistolesi L, Prota G, Rapposelli S, Solati F, Tuccinardi T, Martinelli A, Stossi F, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA, Macchia M (2008) Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta. J Med Chem 51(5):1344–1351. CrossRefPubMedGoogle Scholar
  10. 10.
    Minutolo F, Bertini S, Granchi C, Marchitiello T, Prota G, Rapposelli S, Tuccinardi T, Martinelli A, Gunther JR, Carlson KE, Katzenellenbogen JA, Macchia M (2009) Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta. J Med Chem 52(3):858–867. CrossRefPubMedGoogle Scholar
  11. 11.
    Wang D, Chu PC, Yang CN, Yan R, Chuang YC, Kulp SK, Chen CS (2012) Development of a novel class of glucose transporter inhibitors. J Med Chem 55(8):3827–3836. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hillerns PI, Zu Y, Fu YJ, Wink M (2005) Binding of phytoestrogens to rat uterine estrogen receptors and human sex hormone-binding globulins. Z Naturforsch C 60(7–8):649–656PubMedGoogle Scholar
  13. 13.
    Frolova A, Flessner L, Chi M, Kim ST, Foyouzi-Yousefi N, Moley KH (2009) Facilitative glucose transporter type 1 is differentially regulated by progesterone and estrogen in murine and human endometrial stromal cells. Endocrinology 150(3):1512–1520. CrossRefPubMedGoogle Scholar
  14. 14.
    Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, Pedersen J, Pouliot N, Nadon R, Watt MJ, Taylor RA, Humbert P, Topisirovic I, Larsson O, Risbridger GP, Furic L (2015) Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget 6(2):604–616.
  15. 15.
    Sun L, Zeng X, Yan C, Sun X, Gong X, Rao Y, Yan N (2012) Crystal structure of a bacterial homologue of glucose transporters GLUT1-4. Nature 490(7420):361–366. CrossRefPubMedGoogle Scholar
  16. 16.
    Fiser A, Do RK, Sali A (2000) Modeling of loops in protein structures. Protein Sci 9(9):1753–1773. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cross S, Baroni M, Carosati E, Benedetti P, Clementi S (2010) FLAP: GRID molecular interaction fields in virtual screening. Validation using the DUD data set. J Chem Inf Model 50(8):1442–1450. CrossRefPubMedGoogle Scholar
  18. 18.
    Liu Y, Zhang W, Cao Y, Liu Y, Bergmeier S, Chen X (2010) Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms. Cancer Lett 298(2):176–185. CrossRefPubMedGoogle Scholar
  19. 19.
    Berridge MV, Herst PM, Tan AS (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11:127–152. CrossRefPubMedGoogle Scholar
  20. 20.
    Paterni I, Bertini S, Granchi C, Tuccinardi T, Macchia M, Martinelli A, Caligiuri I, Toffoli G, Rizzolio F, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA, Minutolo F (2015) Highly selective salicylketoxime-based estrogen receptor beta agonists display antiproliferative activities in a glioma model. J Med Chem 58(3):1184–1194. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA (1997) Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36(48):14897–14905. CrossRefPubMedGoogle Scholar
  22. 22.
    Katzenellenbogen JA, Johnson HJ Jr, Myers HN (1973) Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry 12(21):4085–4092CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2018

Authors and Affiliations

  • Carlotta Granchi
    • 1
  • Tiziano Tuccinardi
    • 1
  • Filippo Minutolo
    • 1
    Email author
  1. 1.Department of PharmacyUniversity of PisaPisaItaly

Personalised recommendations